Pain Management Companies

Acorda Therapeutics Phase 3 study evaluating INBRIJA® (dexmedetomidine injection) for the treatment of moderate-to-severe acute low back pain is ongoing. Positive results could expand access to this non-opioid option for pain relief.

Neurolief non-invasive spinal cord stimulation device for chronic neuropathic pain is undergoing a pivotal Phase 3 trial. This technology offers a promising alternative to traditional neurostimulation methods with its ease of use and potentially fewer side effects.

Pfizer Ibogaine-derived drug candidate, PF-05251765, is in early-stage clinical trials for the treatment of neuropathic pain. This novel therapy targets the N-methyl-D-aspartate (NMDA) receptor, potentially offering a new approach to pain management.

Johnson & Johnson acquires Abiomed acquisition strengthens J&J's pain management portfolio with Abiomed's novel spinal cord stimulation technologies.

Stryker Corporation partners with Verily Life Sciences (Alphabet subsidiary) collaboration aims to develop AI-powered solutions for personalized pain management, leveraging Verily's expertise in data analytics and Stryker's medical device technology.

List of Pain Management Key Companies in the Market

• Abbott Laboratories

• Stryker Corporation

• Codman And Shurtleff, Inc

• F. Hoffmann-La Roche Ltd

• Abbvie

• Allergan

• AstraZeneca plc

• Bayer AG

• DJO LLC

• Eli Lilly & Company

• Endo Health Solution